2021-05-21
henlius releases phase iii clinical study results of rituximab injection in ra patients at the 25th national congress of chinese rheumatology
shanghai, china, 20th may, 2021 - shanghai henlius biotech, inc. (2696.hk) announced that the abstract and poster of phase 3 clinical trial (hlx01-ra03，nct03522415) results of hlx01, a rituximab injection which was independently developed by henlius for the treatment of rheumatoid arthritis was reported at the 25th national congress of chinese rheumatology association by the company. this is the first time for henlius to release the results of hlx01-ra03. professor xiaofeng zeng from department of rheumatology and immunology, peking union medical college hospital is the leading principal investigator of this study. this clinical trial data will also be released on the online platform of european congress of rheumatology 2021(eular 2021) in the coming days.
hlx01 ( rituximab injection) is the first monoclonal antibody (mab) biosimilar independently developed by henlius and the first-ever china-manufactured biosimilar approved by the nmpa in accordance with the technical guidelines for the development and evaluation of biosimilars (tentative). it has been approved for the treatment of non-hodgkin's lymphoma and leukemia, covering all the indications approved for the rituximab originator in chinese mainland. since the rituximab originator has not been approved for ra in china, henlius has adopted a differentiated strategy to fully develop the potential of hlx01 (rituximab injection) in ra and to benefit a broader patient population. in december 2020, the national medical products administration (nmpa) has accepted the new drug application (nda) for a new indication of hlx01 to treat ra.
details of the publications of hlx01-ra03:
● title
efficacy and safety of hlx01 in patients with moderately to severely active rheumatoid arthritis who had inadequate responses to methotrexate: results of a randomised, double-blind, placebo-controlled phase 3 study
● leading pi
xiaofeng zeng, md, phd, peking union medical college hospital
● form
abstract and poster
● abstract no.
2099
● study design
hlx01-ra03 is a randomised, double-blind, placebo-controlled, phase 3 study aimed to evaluate the efficacy and safety of hlx01 (rituximab injection) in combination with methotrexate (mtx) in patients with moderate to severe active rheumatoid arthritis (ra) who have had mtx-inadequate response (mtx-ir). eligible patients were randomised 2:1 to receive 1000 mg hlx01 or placebo on day 1 and day 15 by intravenous infusion. patients were retreated with or switched to receive (if initially assigned to placebo) 1000 mg hlx01 on day 169 (the first day of week 24) and day 183. a stable dose of mtx was administered to all patients during the study. patients with inadequate responses at week 16 and week 20 could receive rescue treatments. the primary endpoint of the study is the proportion of patients who met american college of rheumatology 20 (acr20) criteria at week 24.
● results
1) efficacy
a) primary endpoint
275 patients were enrolled (hlx01 group, n = 183; placebo group, n = 92) in this study. a significantly greater proportion of patients achieved acr20 response in the hlx01 group compared with the placebo group in the itt population at week 24 (60.7% vs 35.9%; odds ratio [or], 2.756 [95% ci 1.640, 4.632]; p < 0.001).
b) secondary endpoints
the secondary efficacy endpoints include proportions of patients achieving acr20/50/70, disease activity score measured by 28 joints (das28) based on c-reactive protein (crp) and erythrocyte sedimentation rate (esr), improvement in physical function assessed by health assessment questionnaire-disability index (haq-di), and so on. the results demonstrated that the secondary efficacy endpoints were also significantly improved in hlx01 group compared with placebo group.
2) safety
the overall incidence of treatment emergent adverse events (teaes), adverse drug reactions (adrs), and teaes leading to drug discontinuation were similar among treatment groups.
● conclusion
hlx01 plus mtx showed significantly improved clinical outcomes and comparable safety profiles compared with placebo in chinese patients with moderate to severe active ra who had inadequate responses to mtx, demonstrating hlx01 in combination with mtx as a well-tolerated, safe, and efficient treatment option.
about henlius
henlius (2696.hk) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. up to date, 3 products have been launched in china, 1 in the european union (eu), the new drug applications (ndas) of 3 products accepted for review in china. since its inception in 2010, henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including r&d, manufacturing and commercialisation. it has established global r&d centers and a shanghai-based manufacturing facility certificated by china and the eu good manufacturing practice (gmp).
henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mabs) and has continued to explore immuno-oncology combination therapies with proprietary serplulimab (anti-pd-1 mab) as backbone. apart from the launched products 汉利康® (rituximab), the first china-developed biosimilar, 汉曲优® (trastuzumab, zercepac® in the eu), the first china-developed mab biosimilar approved both in china and in the eu and 汉达远® (adalimumab), the company's first product indicated for autoimmune diseases, the nda of innovative product serplulimab indicated for msi-h solid tumors has been granted priority review, and the ndas of hlx04 (bevacizumab) and hlx01 (rituximab) for the treatment of rheumatoid arthritis are also under review. what's more, henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide, expanding its presence in major market as well as emerging market.
hlx01 ( rituximab injection) is the first monoclonal antibody (mab) biosimilar independently developed by henlius and the first-ever china-manufactured biosimilar approved by the nmpa in accordance with the technical guidelines for the development and evaluation of biosimilars (tentative). it has been approved for the treatment of non-hodgkin's lymphoma and leukemia, covering all the indications approved for the rituximab originator in chinese mainland. since the rituximab originator has not been approved for ra in china, henlius has adopted a differentiated strategy to fully develop the potential of hlx01 (rituximab injection) in ra and to benefit a broader patient population. in december 2020, the national medical products administration (nmpa) has accepted the new drug application (nda) for a new indication of hlx01 to treat ra.
details of the publications of hlx01-ra03:
● title
efficacy and safety of hlx01 in patients with moderately to severely active rheumatoid arthritis who had inadequate responses to methotrexate: results of a randomised, double-blind, placebo-controlled phase 3 study
● leading pi
xiaofeng zeng, md, phd, peking union medical college hospital
● form
abstract and poster
● abstract no.
2099
● study design
hlx01-ra03 is a randomised, double-blind, placebo-controlled, phase 3 study aimed to evaluate the efficacy and safety of hlx01 (rituximab injection) in combination with methotrexate (mtx) in patients with moderate to severe active rheumatoid arthritis (ra) who have had mtx-inadequate response (mtx-ir). eligible patients were randomised 2:1 to receive 1000 mg hlx01 or placebo on day 1 and day 15 by intravenous infusion. patients were retreated with or switched to receive (if initially assigned to placebo) 1000 mg hlx01 on day 169 (the first day of week 24) and day 183. a stable dose of mtx was administered to all patients during the study. patients with inadequate responses at week 16 and week 20 could receive rescue treatments. the primary endpoint of the study is the proportion of patients who met american college of rheumatology 20 (acr20) criteria at week 24.
● results
1) efficacy
a) primary endpoint
275 patients were enrolled (hlx01 group, n = 183; placebo group, n = 92) in this study. a significantly greater proportion of patients achieved acr20 response in the hlx01 group compared with the placebo group in the itt population at week 24 (60.7% vs 35.9%; odds ratio [or], 2.756 [95% ci 1.640, 4.632]; p < 0.001).
b) secondary endpoints
the secondary efficacy endpoints include proportions of patients achieving acr20/50/70, disease activity score measured by 28 joints (das28) based on c-reactive protein (crp) and erythrocyte sedimentation rate (esr), improvement in physical function assessed by health assessment questionnaire-disability index (haq-di), and so on. the results demonstrated that the secondary efficacy endpoints were also significantly improved in hlx01 group compared with placebo group.
2) safety
the overall incidence of treatment emergent adverse events (teaes), adverse drug reactions (adrs), and teaes leading to drug discontinuation were similar among treatment groups.
● conclusion
hlx01 plus mtx showed significantly improved clinical outcomes and comparable safety profiles compared with placebo in chinese patients with moderate to severe active ra who had inadequate responses to mtx, demonstrating hlx01 in combination with mtx as a well-tolerated, safe, and efficient treatment option.
about henlius
henlius (2696.hk) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. up to date, 3 products have been launched in china, 1 in the european union (eu), the new drug applications (ndas) of 3 products accepted for review in china. since its inception in 2010, henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including r&d, manufacturing and commercialisation. it has established global r&d centers and a shanghai-based manufacturing facility certificated by china and the eu good manufacturing practice (gmp).
henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mabs) and has continued to explore immuno-oncology combination therapies with proprietary serplulimab (anti-pd-1 mab) as backbone. apart from the launched products 汉利康® (rituximab), the first china-developed biosimilar, 汉曲优® (trastuzumab, zercepac® in the eu), the first china-developed mab biosimilar approved both in china and in the eu and 汉达远® (adalimumab), the company's first product indicated for autoimmune diseases, the nda of innovative product serplulimab indicated for msi-h solid tumors has been granted priority review, and the ndas of hlx04 (bevacizumab) and hlx01 (rituximab) for the treatment of rheumatoid arthritis are also under review. what's more, henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide, expanding its presence in major market as well as emerging market.